Cancer Treatment Centers of America announced today its plans to launch a new cancer vaccine therapy that expands treatment options for thousands of women with advanced stage ovarian cancer. This innovative treatment will be offered by Cancer Treatment Centers of America and developed by AVAX Technologies, Inc.
"Cancer Treatment Centers of America's number one priority is to help our patients win the battle against cancer," said Dr. Edgar Staren, Chief Medical Officer of Cancer Treatment Centers of America. "This vaccine therapy represents a promising new chapter in the fight against this devastating disease and brings hope to women everywhere."
The breakthrough treatment method uses the patient's own tumor tissues to create a patient-specific vaccine and is combined with chemotherapy delivered directly into the abdominal cavity.
Ovarian cancer, one of the hardest cancers to detect in the early stages, is a very complex disease that is often resistant to chemotherapy. Cancer Treatment Centers of America will offer this new treatment to patients whose cancer has recurred after chemotherapy.
"To win the fight against cancer, it is absolutely vital we do everything we can to make innovative new treatments like this available to patients as soon as possible," said Dr. Staren. It's inconceivable that treatments like these – that give hope to patients – are often left on the laboratory bench, while cancer patients are told there is nothing more that can be done for them."
Cancer Treatment Centers of America expects to start treating patients this summer. This promising vaccine technology hopes to eventually be available to treat other forms of cancer including colorectal and lung cancer patients, as well as patients with malignant melanomas.
Source: Cancer Treatment Center of America
Related stories:
Mayo researchers explore issues related to multiple myeloma treatment
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. Unfortunately, some of the most effective therapies also have toxic side effects that can pose serious health risks and reduce quality of life. In the October issue of
Mayo Clinic Proceedings, two articles authored by Mayo researchers address the issue of how to balance the risks and benefits associated with MM treatments.
CRC screening before Medicare age could save millions in federal health-care dollars
A screening program for colon cancer in patients starting ten years prior to Medicare eligibility, at age 55 instead of Medicare's 65, would save at least two dollars for every dollar spent, according to a new study presented at the American College of Gastroenterology's 73rd Annual Scientific Meeting in Orlando.
New therapeutic treatment approach improves survival in esophageal cancer patients
A study released at the 73rd Annual Scientific Meeting of the American College of Gastroenterology in Orlando found that a new therapeutic treatment, when delivered endoscopically and used in combination with chemotherapy and radiation therapy, improved survival rates in patients with locally advanced esophageal cancer. Cancer of the esophagus often has a poor survival rate.
Pediatric study finds alternatives for radiation of low-grade brain tumors
A multi-institutional study led by researchers at The University of Texas M. D. Anderson Cancer Center has found that using chemotherapy alone and delaying or avoiding cranial radiation altogether can be effective in treating pediatric patients with unresectable or progressive low-grade glioma. The study was presented Sunday at the 40th annual International Society of Pediatric Oncology Meeting in Berlin, Germany.
Study finds genetic variant plays role in cleft lip
University of Iowa researchers and collaborators have found, in a previously identified gene, a variation that likely contributes to one in five cases of isolated cleft lip. It is the first time a genetic variant has been associated with cleft lip alone, rather than both cleft lip and palate.
Battling cancer, one cell at a time
New research suggests that the identification and examination of key cell signaling events required for initiation and progression of cancer might be best accomplished at the single cell level. The research, published by Cell Press in the October issue of the journal
Cancer Cell, provides new insight that may lead to better diagnosis and treatment of some complex cancers.
New Stanford diagnostic test for rare leukemia appears to give faster results, study finds
A new twist on a well-known cell sorting technique may allow physicians to diagnose rare leukemias in hours instead of weeks, according to a study by researchers at the Stanford University School of Medicine and UC-San Francisco. The clinical promise of the Stanford-developed approach, which eavesdrops on individual cells to decipher potentially dangerous molecular conversations, is likely to extend to many other disorders in which cell-signaling pathways are disrupted.
3 share Nobel prize for work on AIDS and cancer
(AP) -- Three European scientists shared the 2008 Nobel Prize in medicine on Monday for separate discoveries of viruses that cause AIDS and cervical cancer, breakthroughs that helped doctors fight the deadly diseases.